New CCRP Trials
by Disease Site

Brain	Breast	Gastro-Intestinal
Genito-Urinary	Head & Neck	Leukemia
Lung	Lymphoma	Melanoma
Myeloma	Cancer Control

Brain
There are no new trials at this time for this disease site.
BACK TO TOP

Breast
NSABP FRP-FB5 (new August 2007)
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. This study will evaluate:

How bevacizumab, given with chemotherapy, and then bevacizumab given with trastuzumab after surgery, will affect breast tumors.
Side effects from adding bevacizumab to chemotherapy and trastuzumab.
Whether adding bevacizumab to chemotherapy and trastuzumab for breast cancer will affect the heart.
If receiving bevacizumab will have any effect on how patients recover from surgery
For further study details and protocol, click here.


NSABP B-41 (new August 2007)
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. Also, the study will look at whether there are gene expression profiles in the tumor tissue that can predict pathologic complete response.
For further study details and protocol, click here.
BACK TO TOP

Gastro-Intestinal
There are no new trials at this time for this disease site.
BACK TO TOP

Genito-Urinary
GOG-0218 (new September 2007)
Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.  Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.  Some block the ability of tumor cells to grow and spread.  Others find tumor cells and help kill them or carry tumor-killing substances to them.  Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.  It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial or primary peritoneal cancer.   This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial or primary peritoneal cancer.
For further study details and protocol, click here.
BACK TO TOP

Head & Neck
BACK TO TOP

Leukemia
There are no new trials at this time for this disease site.
BACK TO TOP

Lung
NCCTG-N0626 (New November 2007)
Pemetrexed disodium and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.  Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.  Giving pemetrexed disodium together with sorafenib may kill more tumor cells.
For further study details and protocol, click here.
BACK TO TOP

Lymphoma
There are no new trials at this time for this disease site.
BACK TO TOP

Melanoma
There are no new trials at this time for this disease site.
BACK TO TOP

Myeloma
Mayo-MC04CC (New November 2007)
This research study is being done to find the highest dose of lenalidomide (a drug) that can be given with melphalan and prednisone without causing bad side effects.
Lenalidomide (CC-5013) is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth.  This study is divided into 2 phases. Phase I will evaluate the best doses of the combination of lenalidomide, melphalan and prednisone. Phase II will further evaluate the dose that is determined to be the best in Phase I and will study how effective the treatment is against multiple myeloma.
For further study details and protocol, click here.
BACK TO TOP

Cancer Control
BACK TO TOP
 

All trial descriptions are abbreviated and provided by the National Cancer Institute. 
For more information and full trial descriptions visit www.cancer.gov.